Genetics influence trial results
When Sandy Patenaude’s MRI showed that her colorectal cancer had spread to her liver and lungs, she was asked to participate in a clinical trial of a cancer stem cell inhibitor drug. In Sandy’s case, the drug successfully prevented her cancer from growing. As a result, doctors are able to determine which patients might benefit from the drug.
Three years ago, Sandy Patenaude was diagnosed with stage 4 inoperable colorectal cancer. She agreed to participate in a clinical trial, testing a new cancer stem cell inhibitor drug. Medical oncologist Dr. Derek Jonker led an international trial at 40 sites with 562 patients, using an experimental drug to target cancer stem cells.
These are the immature cells in a tumour often resistant to standard chemotherapy. While the majority of patients did not respond to the drug, Sandy was one of the 22 percent of patients who did, with her tumours shrinking.
A new trial now underway, targets patients with a similar genetic predisposition to Sandy who are presumed most likely to benefit from the drug. These patients will be identified with the Next Generation DNA Sequencer—a piece of equipment funded with donor support.
You can learn more about Sandy’s journey here.